% | $
Quotes you view appear here for quick access.


you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Mar 27, 2008 9:52 AM Flag

    What is Wrong ?

    Small cap biotech is dead from a retail investor standpoint, and with the price and volume at such small levels, no institution can touch it. This is one of those stocks that will muddle along until a certain milestone brings some niche institution into the market and the stock will double in a heartbeat. Assuming their technology/products holds the promise described in the recent earnings call, a double will be just the start. If they secure a meaningful partnership for Alocrest (i.e. decent money from a notable partner), that could be trigger to bring an institution in. Patience will be rewarded here, IMO.